Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Indoles. Found 14 abstracts

Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Apr 05;378(14):1277-90.   PMCID: PMC5972549
de Oliveira JF, Lima TS, Vendramini-Costa DB, de Lacerda Pedrosa SC, Lafayette EA, da Silva RM, de Almeida SM, de Moura RO, Ruiz A, de Carvalho JE, de Lima M. Thiosemicarbazones and 4-thiazolidinones indole-based derivatives: Synthesis, evaluation of antiproliferative activity, cell death mechanisms and topoisomerase inhibition assay. European journal of medicinal chemistry. 2017 Aug 18;136:305-14.
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Huang Q, He S, Tian Y, Gu Y, Chen P, Li C, Huang J, Liu Y, Yu H, Jin M, Hu S, Tong Q, Ma A, Jin J, Hexner E, Fung H, Reshef R, Zhang Y, Zhang Y. Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. Blood. 2017 May 18;129(20):2737-48.   PMCID: PMC5437825
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
Deng XB, Xiao L, Wu Y, Jin F, Mossman B, Testa JR, Xiao GH. Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy. International journal of cancer. 2015 Jul 15;137(2):481-90.   PMCID: PMC4428975
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50.   PMCID: 4175044
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr;129(1):86-91.   PMCID: PMC 3712785
von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?. Oncology (Williston Park). 2009 Jan;23(1):65-6.   PMCID: PMC 2861343
Wetherbee SL. New weapons to snuff out kidney cancer. Nursing. 2006 Dec;36(12 Pt.1):58-63; quiz 64.
Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, Pehrson JR, Berger JM, Kaufman PD, Adams PD. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Developmental cell. 2005 Jan;8(1):19-30.
O'Dwyer PJ, Laub PB, DeMaria D, Qian M, Reilly D, Giantonio B, Johnston AL, Wu EY, Bauman L, Clendeninn NJ, Gallo JM. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res. 1996 Oct;2(10):1685-92.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Indoles

Indoles Pyrroles therapeutic use drug therapy Renal Cell Carcinoma Kidney Neoplasms Antineoplastic Agents pathology Male Female metabolism adverse effects administration & dosage Aged therapy Disease-Free Survival genetics drug effects Middle Aged methods antagonists & inhibitors Angiogenesis Inhibitors pharmacology Adult Nephrectomy analogs & derivatives Niacinamide Pyrimidines Neoplasm Antigens chemistry blood Disease Progression physiology surgery 80 and over Aged Phenylurea Compounds Double-Blind Method Drug Administration Schedule Carcinogenesis mortality Sulfonamides Organ Sparing Treatments Protein Kinase Inhibitors Neoplasm Metastasis Nephrons Histones Western Blotting Vascular Endothelial Growth Factor A Adjuvant Chemotherapy Tumor Cell Line Treatment Outcome Survival Rate Antitumor Drug Screening Assays pharmacokinetics T-Lymphocytes Neoplasm DNA chemical synthesis DNA interaction immunology Von Hippel-Lindau Tumor Suppressor Protein Minor Histocompatibility Antigens human) 143220-95-5 (PML protein mt [Methods] Antineoplastic Combined Chemotherapy Protocols Lysine Sorafenib Mesothelioma Thymidylate Synthase 0 (Heterochromatin) Transfection Molecular Structure Non-Histone) 0 (Chromosomal Proteins Protein-Tyrosine Kinases Lung Neoplasms Postoperative Care Cell Cycle Methylation Neoplastic Stem Cells Non-US Gov't Support chemically induced Nuclear Proteins Ipilimumab Quality of Life Sunitinib 0 (Nuclear Proteins) 0 (Repressor Proteins) nursing Drug Dose-Response Relationship Fatigue Fever Neoplasm Proteins Non-Histone Chromosomal Proteins Repressor Proteins Gene Expression Regulation Alanine Transaminase Survival Analysis Risk Factors Immunotherapy Isoxazoles du [Diagnostic Use] Middle Age Genetic Therapy EC 3-6-1 (ras Proteins) Area Under Curve Anticancer therapy Recombinant Fusion Proteins Non-US Gov't Research Support Thiosemicarbazones Local Neoplasm Recurrence Fallopian Tube Neoplasms Dosage Compensation (Genetics) Cell Line 0 (macroH2A histone) Clinical Trials as Topic Type II DNA Topoisomerases protein HP-1) Cell Aging Immunohistochemistry Piperazines Enhancer of Zeste Homolog 2 Protein Hematopoietic Stem Cell Transplantation Tumor Biomarkers beta Catenin Metabolic Clearance Rate Genetic Vectors Nude Mice Topoisomerase inhibition Follow-Up Studies Angiopoietin-2 HGF ras Proteins DNA-Binding Proteins cancer stem-like cells Cellular Spheroids Structure-Activity Relationship 0 (Neoplasm Proteins) Resorcinols human) 0 (ASF1A protein Topoisomerase Inhibitors Amino Acid Sequence Phosphorylation 0 (Recombinant Fusion Proteins) US Gov't Support-PHS Oral Administration Cell Death Cell Survival Graft vs Host Disease 0 (Transcription Factors) Cellular death Heterochromatin
Last updated on Friday, January 03, 2020